LMBA02 Protocol for Patients With a Burkitt Lymphoma

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Study ID
NCT00180882
Phase
PHASE3
Status
Unknown

Conditions

  • Burkitt Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt lymphoma or ALL 3.

Key Dates

Start date
Oct 31, 2004
Status verified
Sep 2006

Study Design

Enrollment
260 participants
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Event free survival from date of first randomization

Central Contacts

Related Studies